Paberžės vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 102,841 | 120,885 | 171,110 | 173,719 | 179,141 | 200,790 | 236,514 | 261,516 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 2,204 | 8,210 | 10,864 | 6,897 | 10,576 | -1,266 | 10,650 | 9,063 |
| Equity | 12,089 | 20,299 | 31,164 | 38,060 | 38,636 | 32,370 | 43,020 | 47,083 |
| Liabilities | 19,012 | 18,008 | 16,929 | 9,610 | 17,576 | 25,362 | 23,035 | 20,869 |
| Non-current assets | 10,923 | 10,790 | 10,657 | 10,525 | 19,256 | 17,351 | 15,445 | 13,539 |
| Current assets | 20,178 | 27,517 | 37,436 | 37,145 | 36,956 | 40,381 | 50,610 | 54,413 |
| Total assets | 31,101 | 38,307 | 48,093 | 47,670 | 56,212 | 57,732 | 66,055 | 67,952 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 5,575 | 6,855 | 11,098 |
| Social insurance contributions | - | - | - | - | - | 7,477 | 8,044 | 7,770 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +8.0% | +17.5% | +41.5% | +1.5% | +3.1% | +12.1% | +17.8% | +10.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 7.1% | 21.4% | 22.6% | 14.5% | 18.8% | -2.2% | 16.1% | 13.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 18.2% | 40.4% | 34.9% | 18.1% | 27.4% | -3.9% | 24.8% | 19.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.1% | 6.8% | 6.3% | 4.0% | 5.9% | -0.6% | 4.5% | 3.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.6 | 0.9 | 0.5 | 0.3 | 0.5 | 0.8 | 0.5 | 0.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 25,710 | 30,221 | 42,778 | 43,430 | 44,785 | 50,198 | 59,129 | 66,769 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Paberžės vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-04-16 | 2024-05-08 | 0.31 |
| 2024-03-18 | 2024-04-11 | 0.31 |
| 2024-01-16 | 2024-02-06 | 0.31 |
| 2023-12-18 | 2024-01-02 | 0.31 |
| 2023-11-16 | 2023-12-10 | 0.31 |
| 2023-10-17 | 2023-11-14 | 0.31 |
| 2023-09-18 | 2023-10-10 | 0.31 |
| 2023-08-17 | 2023-09-05 | 0.31 |
| 2023-07-28 | 2023-08-15 | 0.31 |
| 2023-07-24 | 2023-07-25 | 0.31 |
| 2023-04-18 | 2023-04-18 | 522.60 |
| 2022-08-23 | 2022-09-05 | 0.65 |
| 2022-07-25 | 2022-08-02 | 0.65 |
| 2022-06-16 | 2022-06-27 | 72.51 |
| 2022-05-17 | 2022-06-01 | 72.51 |
Paberžės vaistinė - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Paberžes vaistine, UAB (code 186110064) is a private limited liability company engaged in the retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of €261.5K, up 10.6% year on year and 30.2% over two years. Net profit was €9.1K, with a profit margin of 3.5%. This followed a loss of €1.3K in 2023 and a stronger profit of €10.7K in 2024, indicating a return to profitability in 2024 and continued positive earnings in 2025, albeit at a slightly lower level. The balance sheet remained stable, with total assets of €68.0K, equity of €47.1K and liabilities of €20.9K. Long-term assets stood at €13.5K and short-term assets at €54.4K. Key ratios indicate solid capitalisation and efficient use of assets: equity ratio was 69.3%, debt-to-equity 0.44, ROE 19.2%, ROA 13.3% and asset turnover 3.85x. Revenue per employee was €87.2K and profit per employee €3.0K.